Celemics announced its expansion into the North American market with the establishment of Celemics America, Inc. Celemics America, Inc. will initiate commercial operations in the U.S. with a primary goal of expanding this technology to North American markets to make contributions to Precision, or Personalized Medicine. Precision Medicine is the term used by medical and healthcare professionals to describe the emerging approach to coordinate disease prevention and treatment based upon an individual's lifestyle patterns and genetic variability. Celemics America's product line will consist of both pre-defined and custom content Next Generation Sequencing test kits and panels.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,825 KRW | -0.78% | +0.13% | -9.57% |
2022 | Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index | CI |
2021 | Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.57% | 22.8M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- A331920 Stock
- News Celemics, Inc.
- Celemics Announces Expansion into North America with the Commencement of Celemics America, Inc